A Randomized, Double blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects with Moderate to Severe Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2018
At a glance
- Drugs Abrilumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Amgen
- 16 Apr 2018 Status changed from active, no longer recruiting to completed.
- 02 Feb 2017 Planned End Date changed from 1 Nov 2019 to 1 Apr 2018.
- 29 May 2016 This trial has been terminated in Denmark.